Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEONID SHUNYAKOV

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1396709895
CMS profile
335741
Location
BOLIVAR, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$327,068.46

442 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 9; records 51–100 of 442 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEONID SHUNYAKOV

NPI 1396709895 · CMS profile ID 335741

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BOLIVAR, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 9; records 51–100 of 442 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396709895?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEONID SHUNYAKOV, NPI 1396709895, CMS profile ID 335741. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 442 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396709895?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LEONID SHUNYAKOV, NPI 1396709895, CMS profile ID 335741. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 9; records 51–100 of 442 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396709895?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LEONID SHUNYAKOV, NPI 1396709895, CMS profile ID 335741, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 9; records 51–100 of 442 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1396709895?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

442 matching records · $327,068.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 442 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 442.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $121.5812/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150212817 CMS
E.R. Squibb & Sons, L.L.C. $4.6312/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101327610 CMS
Janssen Biotech, Inc. $5.5012/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078779723 CMS
Janssen Biotech, Inc. $160.6311/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078779855 CMS
Regeneron Healthcare Solutions, Inc. $3,684.0011/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114171536 CMS
Genmab U.S., Inc. $15.8711/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828898 CMS
Janssen Biotech, Inc. $554.0911/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078779714 CMS
Janssen Biotech, Inc. $49.5011/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078779884 CMS
Rigel Pharmaceuticals, Inc. $24.0711/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145206225 CMS
Novocure Inc. $93.4011/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123337058 CMS
Celgene Corporation $12.0311/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101110144 CMS
Daiichi Sankyo Inc. $5,360.0011/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089482827 CMS
Regeneron Healthcare Solutions, Inc. $101.2511/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114171534 CMS
AstraZeneca Pharmaceuticals LP $1,340.0011/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104736447 CMS
ABBVIE INC. $118.2611/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106095427 CMS
ABBVIE INC. $235.8411/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106095429 CMS
Amgen Inc. $11.6011/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111707300 CMS
Genmab U.S., Inc. $4,680.0011/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828888 CMS
Novartis Pharmaceuticals Corporation $9.0011/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087213615 CMS
Novartis Pharmaceuticals Corporation $0.2011/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087213617 CMS
Novartis Pharmaceuticals Corporation $14.3311/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087213621 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.6311/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117993172 CMS
Gilead Sciences, Inc. $15.4711/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133832209 CMS
GlaxoSmithKline, LLC. $471.9511/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116549719 CMS
Astellas Pharma US Inc $5.8011/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139431932 CMS
AstraZeneca Pharmaceuticals LP $5,360.0011/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104378349 CMS
Celgene Corporation $16.2211/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101110140 CMS
Daiichi Sankyo Inc. $2,680.0011/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089482825 CMS
GlaxoSmithKline, LLC. $16.2910/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115823161 CMS
Janssen Biotech, Inc. $54.9910/30/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078779658 CMS
ABBVIE INC. $4,725.0010/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106095425 CMS
AstraZeneca Pharmaceuticals LP $25.9510/29/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105473993 CMS
AstraZeneca Pharmaceuticals LP $250.0010/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105896734 CMS
Gilead Sciences, Inc. $71.6510/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133832207 CMS
GlaxoSmithKline, LLC. $2.5310/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116535488 CMS
Daiichi Sankyo Inc. $29.5110/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089482821 CMS
ABBVIE INC. $31.6010/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106095423 CMS
Genmab U.S., Inc. $44.0010/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828884 CMS
Genmab U.S., Inc. $37.5210/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828886 CMS
Genmab U.S., Inc. $31.4610/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828890 CMS
Genmab U.S., Inc. $22.4810/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828894 CMS
Amgen Inc. $160.3810/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117683828 CMS
Genmab U.S., Inc. $396.5910/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828882 CMS
Genmab U.S., Inc. $623.9610/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828892 CMS
Genmab U.S., Inc. $16.3610/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828896 CMS
Gilead Sciences, Inc. $16.2010/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133832205 CMS
Amgen Inc. $122.1210/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117683824 CMS
Daiichi Sankyo Inc. $493.1210/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089482831 CMS
AstraZeneca Pharmaceuticals LP $300.0010/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105837893 CMS
Rigel Pharmaceuticals, Inc. $4.4410/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145206227 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $324,796.96 410
PY2020 $129,096.10 205
PY2021 $233,777.75 277
PY2022 $334,003.60 455
PY2023 $348,699.85 445
PY2024 $327,068.46 442
PY2025 $389,146.89 417

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $12,457.56 11
PY2024 Principal investigator $113,549.17 30
PY2023 Recipient $1,734.05 1
PY2023 Principal investigator $159,918.88 34
PY2022 Principal investigator $155,538.67 49
PY2021 Recipient $815.45 1
PY2021 Principal investigator $143,240.51 97
PY2020 Principal investigator $57,996.88 32
PY2019 Recipient $961.88 1
PY2019 Principal investigator $85,571.90 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $196.00 11/07/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737881
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $353.60 11/07/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737883
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,035.00 11/07/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737885
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,040.20 09/18/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) No dispute reported 06/30/2026 1223285688
Principal investigator 1 Mirati Therapeutics, Inc. $5,246.16 07/08/2025 Non-covered Recipient Entity
Central Care Cancer Center
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236531197
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $925.00 04/28/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737875
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $822.00 04/28/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737877
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $104.00 04/28/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737879
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $249.60 01/23/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737871
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $156.00 01/07/2025 Non-covered Recipient Entity
CENTRAL CARE CANCER CENTER
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737873
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $330.00 01/03/2025 Non-covered Recipient Entity
Central Care Cancer Center
A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma No dispute reported 06/30/2026 1235998214